Reported 2 days ago
Citizens JMP has reiterated its Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX), setting a price target of $31. The biopharmaceutical company reported record net product revenue for its hepatitis B vaccine, HEPLISAV-B, at $65 million in fiscal Q1 2025, marking a 36% year-over-year increase. Furthermore, Dynavax is advancing new vaccine programs for pandemic influenza and Lyme disease, with clinical developments expected in the next few years.
Source: YAHOO